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Background: Tocilizumab (TCZ) is indicated for RA patients with
inadequate responses to DMARDs, either as monotherapy (Mono) or in
combination with DMARDs (Combo). ACT-UP pools data from several
international, observational, post-marketing studies of i.v. TCZ. Interim
observations of patterns of TCZ-use in RA patients, adherence to label
recommendations and safety are reported.
Methods: Adult patients with moderate-to-severe RA who started TCZ
in routine practice were observed in clinical practice for 6 months.
There were no specified dosing regimens (concomitant RA treatments
permitted) and no interventional procedures, clinic visits, or laboratory
analyses outside routine practice.
Results: Data are reported for 961 patients receiving TCZ [352 (37%)
initiated as Mono and 609 (63%) as Combo]. 94% and 95% of Mono
and Combo patients, respectively, started TCZ at 8 mg/kg, and 93%
and 94% of patients, respectively, taking TCZ at 6 months received
8 mg/kg. TCZ dose changes occurred in 34 (10%) Mono patients
(7 increased, 11 decreased, 16 increased and decreased) and 68
(11%) Combo patients (13 increased, 20 decreased, 35 increased and
decreased). Reasons for dose changes were: adverse events (AEs; 4%
Mono; 5% Combo) and lack of efficacy (2% Mono; 1% Combo).
Median MTX dose for Combo patients was 15.0 mg/week. 63 patients
changed MTX dose (median dose change 5.0 mg/week). 28 (8%) of
TCZ mono patients added a DMARD during the study. Corticosteroids
were used by 57% of Mono and 70% of Combo patients (median
prednisone-equivalent dose (at baseline) 7.5 and 5.0 mg/day, respec-
tively). At 6 months, 72% of Mono and 84% of Combo patients were
still receiving TCZ. 100 (10%) patients discontinued TCZ in the first
3 months; 94 (10%) in the next 3 months (reasons: lack of efficacy
(11% Mono; 27% Combo), AEs (27% Mono; 29% Combo), other
reasons (62% Mono; 44% Combo). AEs occurred in 53% of patients
(Table 1). Infections were less common in Mono patients. No
gastrointestinal perforations were reported.
Conclusion: In clinical practice, 37% of patients started TCZ as
monotherapy and most patients continued with TCZ treatment (Mono
and Combo) 6 months after initiation. TCZ was well tolerated in both
groups.
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E42 TABLE 1. Safety data from ACT-UP (6 months)
TCZ Mono
(n¼ 352)
TCZ Combo
(n¼609)
All patients
(n¼ 961)
AEs, n (%) 185 (52.6) 324 (53.2) 509 (53.0)
Rate per 100 py 193 205 201
AEs by SOCa
Infections and infestations 56 (15.9) 132 (21.7) 188 (19.6)
Investigations 38 (10.8) 71 (11.7) 109 (11.3)
Musculoskeletal and connective
tissue disorders
33 (9.4) 52 (8.5) 85 (8.8)
Gastrointestinal disorders 29 (8.2) 49 (8.0) 78 (8.1)
Skin and s.c. tissue disorders 28 (8.0) 44 (7.2) 72 (7.5)
General disorders and administration
site conditions
22 (6.3) 34 (5.6) 56 (5.8)
Blood and lymphatic system disorders 20 (5.7) 44 (7.2) 64 (6.7)
Nervous system disorders 18 (5.1) 32 (5.3) 50 (5.2)
Metabolism and nutrition disorders 18 (5.1) 23 (3.8) 41 (4.3)
SAEs, n (%) 34 (9.7) 49 (8.0) 83 (8.6)
Rate per 100 py 23 19 21
Infection SAEs, n (%) 6 (1.7) 15 (2.5) 21 (2.2)
Total AEs leading to withdrawal, n (%) 32 (9.1) 42 (6.9) 74 (7.7)
Rate per 100 py) 21 14 16
AEs leading to withdrawal by SOCb
Skin and s.c. tissue disorders, n (%) 6 (1.7) 5 (0.8) 11 (1.1)
Infections and infestations, n (%) 5 (1.4) 6 (1.0) 11 (1.1)
Gastrointestinal disorders, n (%) 4 (1.1) 1 (0.2) 5 (0.5)
Cardiac disorders, n (%) 4 (1.1) — 4 (0.4)
Blood and lymphatic system
disorders, n (%)
3 (0.9) 7 (1.1) 10 (1.0)
Rate per 100 py is based on total number of events during TCZ exposure,
determined for each patient as date of last TCZ dosedate of first TCZ doseþ 28
days. aReported in 5% of patients in a treatment group. bReported in 1% of
patients in a treatment group. Combo: in combination with DMARDs; Mono:
monotherapy; py: patient-years; SAEs: serious AEs; SOC: system organ class;
TCZ: tocilizumab.
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